At CD BioGlyco, we are dedicated to the development of various types of Glycosylation Inhibitors. For example, Metabolic Interconversion Inhibitor Development Service, N-Glycosylation Inhibitor Development Service, O-Glycosylation Inhibitor Development Service, Capping Modification Inhibitor Development Service, and so on. As for capping modification inhibitor development, we provide inhibitor development solutions for each of the fucosyltransferases through functional characterization of the enzyme.
Our inhibitor development focuses on the following processes:
The specific services we provide include but are not limited to:
Fig.1 Types of fucosyltransferase inhibitors. (CD BioGlyco)
α-1,2-Fucosyltransferase is a rate-limiting enzyme whose catalytic activity is commonly associated with cancer development. At CD BioGlyco, we develop α-1,2-fucosyltransferase inhibitors by probing the role played by α-1,2-fucosyltransferase during fucosylation of cells.
α-1,3-Fucosyltransferases catalyze the fucosylation of the glycan backbone in a non-site-specific manner, yielding compounds with different degrees of fucosylation. At CD BioGlyco, we develop α-1,3-fucosyltransferase inhibitors based on the catalytic mechanism of α-1,3-fucosyltransferase.
α-1,6 Fucosyltransferase catalyzes certain cancers in which the tumor cell surface receptor binds to the fucose and thus causes the tumor cells to spread. At CD BioGlyco, we provide our clients with α-1,6 fucosyltransferase inhibitor development services based on the principle of action of α-1,6 fucosyltransferase.
CD BioGlyco has extensive experience in the development of glycosylation inhibitors, providing many types of glycosylation inhibitor development. Every step of our process has gone through multiple quality checks to ensure that we provide our clients with satisfactory development programs and results. Please feel free to contact us if you are interested in our services and have any questions.